ITOS - Iteos Therapeutics - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart

Iteos Therapeutics's activity chart (see below) currently has 65 price targets and 46 ratings on display.

Stock Analyst Price Targets - Review

Analysts' price targets on this stock were met 17.37% of the time, taking 108.71 days on average.

Most recent stock forecast was given by EVA FORTEA VERDEJO from WELLS FARGO on 07-Aug-2025. First documented stock forecast 18-Aug-2020.

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold Since 07-Aug-2025

$11

$12

1 years 3 months 15 days ago
(07-Aug-2025)

0/6 (0%)

$0.87 (8.59%)

Hold Since 22-Jul-2025

$10

$9

1 years 4 months ago
(22-Jul-2025)

3/6 (50%)

$-0.12 (-1.19%)

240

Buy Since 18-Aug-2020

$12

$18

1 years 5 months 25 days ago
(28-May-2025)

2/8 (25%)

$1.94 (19.28%)

281

Buy Since 05-May-2021

$46

1 years 6 months 8 days ago
(14-May-2025)

1/11 (9.09%)

$38.9 (547.89%)

198

Buy Since 16-Mar-2023

$8

$27

1 years 6 months 9 days ago
(13-May-2025)

1/4 (25%)

$0.15 (1.91%)

6

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is ITOS (Iteos Therapeutics) average time for price targets to be met?

On average it took 109 days for the stock forecasts to be reached, with an average price target met ratio of 17.37%.

Which analyst most recently updated their price target on ITOS (Iteos Therapeutics)?

Eva Fortea Verdejo

Which analyst has the lowest performance score on ITOS (Iteos Therapeutics) with a proven track record?

EVA FORTEA VERDEJO

Which analyst has the most public recommendations on ITOS (Iteos Therapeutics)?

Eva Fortea Verdejo works at WELLS FARGO and has 13 price targets and 8 ratings on ITOS

Which analyst is the currently most bullish on ITOS (Iteos Therapeutics)?

Christopher Raymond with the highest potential upside of $25.85

Which analyst is the currently most reserved on ITOS (Iteos Therapeutics)?

Christopher Neyor with the lowest potential downside of -$2.15
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

To continue looking at analysts data please register to the advanced membership

What is AnaChart?